Ramelteon

雷美替胺

Report date: 2026/05/12 20:00:17
NMEFirst In Class

Base Information

Drug NameRamelteon
Drug Alias NameRamelteonum雷美尔通雷美替昂瑞美替昂拉米替隆 +[9] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMelatonin receptor 1A agonistsMelatonin receptor 1B agonists
TargetsMelatonin receptor 1AMelatonin receptor 1B
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Depressive DisorderBipolar Disorder +[15] 
Global Approved IndicationsSleep Initiation and Maintenance Disorders
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2005/07/22
Country/TerritoryCzechiaBelgiumBulgaria +[22] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTakeda Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTakeda Pharmaceuticals USA IncTakeda Pharmaceutical Co LtdSichuan Credit Pharmaceutical Co Ltd
Inactive CompaniesSwedish Medical Center-Radia Issaquah Imaging Center LlcAssociação Fundo De Incentivo À PesquisaUniversity Of Pennsylvania +[4] 
Active IndicationsSleep Initiation and Maintenance Disorders
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Depressive DisorderBipolar Disorder +[14] 

Other Information

ATC CodeN05CH02
Related LinksWikipediaDrugBankKEGG